After steering Metsera through its $10 billion acquisition by Pfizer in 2025, Matthew Lang has joined Structure Therapeutics as chief operating officer and general counsel. FierceBiotech reports that Lang will help move Structure’s oral, once‑daily GLP‑1 candidate aleniglipron into phase 3 trials, following phase 2 data showing 16 percent weight loss, described by the company as the strongest result yet for an oral GLP‑1 therapy. Lang previously held senior legal roles at Lyell Immunopharma, Myovant Sciences and Gilead Sciences. Meanwhile, Vir Biotechnology’s chief medical officer Mark Eisner, M.D., plans to depart on April 24 after less than two years. And over at Leal Therapeutics, two Eli Lilly veterans, Johannes Tauscher, M.D., and Raymond Jordt, are taking on chief medical and chief business roles to push forward the company’s schizophrenia and ALS programs.
This wave of leadership reshuffling shows how dealmakers and clinical operators are circling between metabolic and neuroscience biotechs rather than Big Pharma. Lang’s appointment positions Structure Therapeutics to tap the mounting investor demand for oral GLP‑1s, still a hot pursuit as companies chase the injectable incumbents that dominate obesity and diabetes. Should Structure’s phase 3 data hold near that 16 percent weight‑loss signal, it would become a serious contender in the oral peptide race tracked on RxInfo.ai. Lang’s deal experience from Metsera’s Pfizer sale isn’t just résumé polish; it signals Structure’s ambition to stay acquisition‑ready as late‑stage trials mature. And yes, that readiness matters, private equity and large pharmas are watching every oral GLP‑1 readout closely right now.
Vir’s CMO exit tells a different story: post‑pandemic uncertainty and strategic retooling continue to buffet infectious‑disease specialists. Eisner, recruited in mid‑2024 as part of a broader C‑suite reset, leaves amid what looks like ongoing internal friction as Vir refines its focus beyond COVID‑era programs. Meanwhile, Leal’s recruitment of former big‑pharma R&D and business‑development leaders from Lilly and Takeda marks renewed capital formation in small‑molecule neuropsychiatry. That space, long underpopulated with experienced operators since the big players retreated from CNS research a decade ago, is waking up again. If Leal’s hires can translate their pharma pedigree into real clinical progress, venture syndicates are likely to return to next‑generation CNS assets in 2026. Nobody really knows how fast that cycle will move, but the early signals are there, and they’re getting harder to ignore.
